ADXS reported FY3Q17 financials yesterday, and the cash burn was high. Moreover, the start of the phase-1 NEO trial is delayed until 1H18 for undisclosed reasons. The HER2 program has been discontinued.
If all that weren't enough, the company still hasn't named a permanent CEO or explained why the previous CEO was fired.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.